The AJAX is more than just an armored vehicle—it’s a battlefield intelligence platform designed to detect threats, gather real-time information, and help commanders make faster decisions. In this ...

Eli Lilly’s up-to-$2.3 billion acquisition of Ajax Therapeutics is facing its first major public test, and the initial clinical data show why the pharma giant made the bet. The Ajax acquisition was a ...

Add Yahoo as a preferred source to see more of our stories on Google. MPs have questioned whether the Army's troubled £6.3 billion Ajax armoured vehicle will ever be fit for use in combat. The project ...

Anthropic is regarded as a giant among AI companies, but perhaps what it really excels in is anthropomorphism. Earlier this year, the company released an 84-page document titled Claude’s “constitution ...

You’re invited to participate in a series of special events to honour veterans and celebrate local history in Ajax as the town commemorates a significant event. The Town of Ajax is hosting a series of ...

Nahda Nabiilah is a writer and editor from Indonesia. She has always loved writing and playing games, so one day she decided to combine the two. Most of the time, writing gaming guides is a blast for ...

Trials of the British Army’s Ajax armoured vehicles are set to resume, despite major delays amid concern for soldiers’ safety. Minister for Defence Readiness and Industry Luke Pollard announced in ...

In a stealth move fitting of an announcement it wants to hide, the government has come up with a "do nothing" solution to a desperate military need – a decision that's as feeble as the equipment ...

A Belgian murder mystery that claims to be anything but is the surrealist premise of art-meets-death series This Is Not A Murder Mystery, which sees a bunch of famous artists trapped in an estate with ...

Eli Lilly (LLY) has agreed to acquire biopharmaceutical company Ajax Therapeutics for up to $2.3B in cash, inclusive of an upfront payment and subsequent payments upon the achievement of certain ...

Eli Lilly & Co. agreed to buy closely held Ajax Therapeutics Inc. for as much as $2.3 billion in cash, part of its effort to build out a portfolio of breakthrough cancer therapies. Ajax’s lead ...